Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intermedics enters International classification of disease (ICD) market:

This article was originally published in Clinica

Executive Summary

A new competitor has entered the US defibrillator market following FDA approval of Intermedics' Res-Q ACD. "This system's major strengths include its programming flexibility, individualised therapy for multiple dysrhythmias and 40-joule output," says Michael Rousseau, Intermedics' vice-president of marketing. He adds that Intermedics is the only manufacturer to provide a sterile package which allows complete pre-implant testing, thereby reducing the need for additional equipment. Intermedics (part of Sulzermedica) joins Medtronic, Guidant and Ventritex in the US ICD market which is estimated at $518 million (see Clinica No 658, p 9).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel